N-piperidinyl acetamide derivatives for selective T-type calcium channel blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with T-type calcium channel activity, such as cardiovascular disease, epilepsy, cancer, and pain, often have limitations in selectivity and side effects, and there is a need for compounds that effectively modulate T-type calcium channels without interfering with other critical ion channels like hERG K+ channels.
Innovation Solution
A pharmaceutical composition comprising a substituted amino N-piperidinyl acetamide derivative that selectively blocks T-type calcium channels, enhancing calcium channel blocking activity while minimizing activity on the hERG K+ channel to reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current calcium channel blockers are used to treat conditions associated with T-type calcium channel activity, then therapeutic effects are achieved, but selectivity is reduced and side effects increase
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (N-piperidinyl acetamide derivative with particular substituents) that confer selective affinity for T-type calcium channels. The molecular structure is locally optimized with specific functional groups and spatial arrangement to interact preferentially with T-type channel binding sites, achieving therapeutic effects while minimizing off-target effects on other ion channels.
Solution Approach 2:
The patent employs parameter changes by modifying physical and chemical parameters of the calcium channel blocker compound, including molecular weight, lipophilicity, and structural configuration. These parameter adjustments optimize the compound's selectivity profile, enhancing its ability to discriminate between T-type calcium channels and other ion channels like hERG K+ channels, thereby reducing side effects while maintaining therapeutic efficacy.
2Adaptability or versatility
If calcium channel blockers with broad activity are used, then multiple conditions can be treated, but interference with other critical ion channels increases
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic target space into specific T-type calcium channel subtypes and other ion channels. The compound is designed to segment its pharmacological activity, showing preferential binding to T-type channels while exhibiting minimal activity on hERG K+ channels and other critical ion channels. This segmented selectivity allows broad therapeutic applicability across multiple conditions without causing harmful channel interference.
3Reliability
If existing anticonvulsant drugs are used to block T-type channels, then seizure activity is reduced, but selectivity over other channels is compromised
Solution Approach 1:
The patent employs the intermediary principle by introducing a carefully designed molecular structure that acts as a selective intermediary between the drug and the ion channel. The N-piperidinyl acetamide derivative with specific substituents serves as a precision intermediary that mediates interaction exclusively with T-type calcium channels, achieving reliable anticonvulsant effects while maintaining high channel selectivity and avoiding off-target effects.
Data Source
AI summary
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity, are disclosed. Specifically, a series of compounds which are N-piperidinyl acetamide derivatives as shown in formula (1) are disclosed as calcium ion channel activating modulators. Compositions comprising these compounds and the use of these compounds in the treatment or prevention of conditions such as epilepsy are also disclosed.